false2026Q10001682852December 31P9Mhttp://fasb.org/us-gaap/2025#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationhttp://fasb.org/us-gaap/2025#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationhttp://fasb.org/us-gaap/2025#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2025#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2025#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2025#OtherLiabilitiesCurrentxbrli:sharesiso4217:USDiso4217:USDxbrli:sharesmrna:productmrna:candidatemrna:developmentProgrammrna:securityutr:sqftmrna:extensionxbrli:puremrna:lawsuitmrna:claim00016828522026-01-012026-03-3100016828522026-04-2400016828522026-03-3100016828522025-12-310001682852mrna:ProductSalesMember2026-01-012026-03-310001682852mrna:ProductSalesMember2025-01-012025-03-310001682852us-gaap:ProductAndServiceOtherMember2026-01-012026-03-310001682852us-gaap:ProductAndServiceOtherMember2025-01-012025-03-3100016828522025-01-012025-03-310001682852us-gaap:CommonStockMember2025-12-310001682852us-gaap:AdditionalPaidInCapitalMember2025-12-310001682852us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-310001682852us-gaap:RetainedEarningsMember2025-12-310001682852us-gaap:CommonStockMember2026-01-012026-03-310001682852us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310001682852us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-012026-03-310001682852us-gaap:RetainedEarningsMember2026-01-012026-03-310001682852us-gaap:CommonStockMember2026-03-310001682852us-gaap:AdditionalPaidInCapitalMember2026-03-310001682852us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-03-310001682852us-gaap:RetainedEarningsMember2026-03-310001682852us-gaap:CommonStockMember2024-12-310001682852us-gaap:AdditionalPaidInCapitalMember2024-12-310001682852us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001682852us-gaap:RetainedEarningsMember2024-12-3100016828522024-12-310001682852us-gaap:CommonStockMember2025-01-012025-03-310001682852us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310001682852us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310001682852us-gaap:RetainedEarningsMember2025-01-012025-03-310001682852us-gaap:CommonStockMember2025-03-310001682852us-gaap:AdditionalPaidInCapitalMember2025-03-310001682852us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-310001682852us-gaap:RetainedEarningsMember2025-03-3100016828522025-03-310001682852us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2025-12-310001682852us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2025-12-310001682852us-gaap:AccumulatedTranslationAdjustmentMember2025-12-310001682852us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2026-01-012026-03-310001682852us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2026-01-012026-03-310001682852us-gaap:AccumulatedTranslationAdjustmentMember2026-01-012026-03-310001682852us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2026-03-310001682852us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2026-03-310001682852us-gaap:AccumulatedTranslationAdjustmentMember2026-03-310001682852mrna:ProductSalesMembercountry:US2026-01-012026-03-310001682852mrna:ProductSalesMembercountry:US2025-01-012025-03-310001682852mrna:ProductSalesMembersrt:EuropeMember2026-01-012026-03-310001682852mrna:ProductSalesMembersrt:EuropeMember2025-01-012025-03-310001682852mrna:ProductSalesMembermrna:RestOfTheWorldMember2026-01-012026-03-310001682852mrna:ProductSalesMembermrna:RestOfTheWorldMember2025-01-012025-03-310001682852mrna:COVID19Member2026-01-012026-03-310001682852mrna:COVID19Member2025-01-012025-03-310001682852mrna:RSVMember2026-01-012026-03-310001682852mrna:RSVMember2025-01-012025-03-310001682852mrna:ProductSalesMember2025-12-310001682852mrna:ProductSalesMember2026-03-310001682852mrna:StandReadyManufacturingMember2026-01-012026-03-310001682852mrna:StandReadyManufacturingMember2025-01-012025-03-310001682852mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember2026-01-012026-03-310001682852mrna:CollaborationArrangementIncludingArrangementsWithAffiliateMember2025-01-012025-03-310001682852us-gaap:GrantMember2026-01-012026-03-310001682852us-gaap:GrantMember2025-01-012025-03-310001682852mrna:LicenseAndRoyaltyMember2026-01-012026-03-310001682852mrna:LicenseAndRoyaltyMember2025-01-012025-03-310001682852mrna:MerckMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2022-10-310001682852mrna:MerckMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2026-01-012026-03-310001682852mrna:MerckMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2025-01-012025-03-310001682852mrna:RecordatiS.p.AMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2026-03-160001682852mrna:BlackstoneLifeSciencesBlackstoneMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2024-03-310001682852mrna:BlackstoneLifeSciencesBlackstoneMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2026-01-012026-03-310001682852mrna:BlackstoneLifeSciencesBlackstoneMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2025-01-012025-03-310001682852us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Member2026-03-310001682852us-gaap:CashAndCashEquivalentsMemberus-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Member2026-03-310001682852us-gaap:CashAndCashEquivalentsMembermrna:CurrentMarketableSecuritiesMemberus-gaap:FairValueInputsLevel1Member2026-03-310001682852us-gaap:CashAndCashEquivalentsMembermrna:NoncurrentMarketableSecuritiesMemberus-gaap:FairValueInputsLevel1Member2026-03-310001682852us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel2Member2026-03-310001682852us-gaap:CertificatesOfDepositMemberus-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel2Member2026-03-310001682852us-gaap:CertificatesOfDepositMembermrna:CurrentMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Member2026-03-310001682852us-gaap:CertificatesOfDepositMembermrna:NoncurrentMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Member2026-03-310001682852us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel2Member2026-03-310001682852us-gaap:USTreasurySecuritiesMemberus-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel2Member2026-03-310001682852us-gaap:USTreasurySecuritiesMembermrna:CurrentMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Member2026-03-310001682852us-gaap:USTreasurySecuritiesMembermrna:NoncurrentMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Member2026-03-310001682852us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2026-03-310001682852us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel2Member2026-03-310001682852us-gaap:USGovernmentAgenciesDebtSecuritiesMembermrna:CurrentMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Member2026-03-310001682852us-gaap:USGovernmentAgenciesDebtSecuritiesMembermrna:NoncurrentMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Member2026-03-310001682852us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2026-03-310001682852us-gaap:CorporateDebtSecuritiesMemberus-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel2Member2026-03-310001682852us-gaap:CorporateDebtSecuritiesMembermrna:CurrentMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Member2026-03-310001682852us-gaap:CorporateDebtSecuritiesMembermrna:NoncurrentMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Member2026-03-310001682852us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2026-03-310001682852us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel2Member2026-03-310001682852us-gaap:USGovernmentDebtSecuritiesMembermrna:CurrentMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Member2026-03-310001682852us-gaap:USGovernmentDebtSecuritiesMembermrna:NoncurrentMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Member2026-03-310001682852us-gaap:FairValueInputsLevel2Member2026-03-310001682852us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel2Member2026-03-310001682852mrna:CurrentMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Member2026-03-310001682852mrna:NoncurrentMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Member2026-03-310001682852us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Member2025-12-310001682852us-gaap:CashAndCashEquivalentsMemberus-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Member2025-12-310001682852us-gaap:CashAndCashEquivalentsMembermrna:CurrentMarketableSecuritiesMemberus-gaap:FairValueInputsLevel1Member2025-12-310001682852us-gaap:CashAndCashEquivalentsMembermrna:NoncurrentMarketableSecuritiesMemberus-gaap:FairValueInputsLevel1Member2025-12-310001682852us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel2Member2025-12-310001682852us-gaap:CertificatesOfDepositMemberus-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel2Member2025-12-310001682852us-gaap:CertificatesOfDepositMembermrna:CurrentMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Member2025-12-310001682852us-gaap:CertificatesOfDepositMembermrna:NoncurrentMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Member2025-12-310001682852us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel2Member2025-12-310001682852us-gaap:USTreasurySecuritiesMemberus-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel2Member2025-12-310001682852us-gaap:USTreasurySecuritiesMembermrna:CurrentMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Member2025-12-310001682852us-gaap:USTreasurySecuritiesMembermrna:NoncurrentMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Member2025-12-310001682852us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2025-12-310001682852us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel2Member2025-12-310001682852us-gaap:USGovernmentAgenciesDebtSecuritiesMembermrna:CurrentMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Member2025-12-310001682852us-gaap:USGovernmentAgenciesDebtSecuritiesMembermrna:NoncurrentMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Member2025-12-310001682852us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2025-12-310001682852us-gaap:CorporateDebtSecuritiesMemberus-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel2Member2025-12-310001682852us-gaap:CorporateDebtSecuritiesMembermrna:CurrentMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Member2025-12-310001682852us-gaap:CorporateDebtSecuritiesMembermrna:NoncurrentMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Member2025-12-310001682852us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2025-12-310001682852us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel2Member2025-12-310001682852us-gaap:USGovernmentDebtSecuritiesMembermrna:CurrentMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Member2025-12-310001682852us-gaap:USGovernmentDebtSecuritiesMembermrna:NoncurrentMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Member2025-12-310001682852us-gaap:FairValueInputsLevel2Member2025-12-310001682852us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel2Member2025-12-310001682852mrna:CurrentMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Member2025-12-310001682852mrna:NoncurrentMarketableSecuritiesMemberus-gaap:FairValueInputsLevel2Member2025-12-310001682852us-gaap:USTreasuryBillSecuritiesMember2026-03-310001682852us-gaap:USTreasuryNotesSecuritiesMember2026-03-310001682852us-gaap:CorporateDebtSecuritiesMember2026-03-310001682852us-gaap:USGovernmentDebtSecuritiesMember2026-03-310001682852us-gaap:USTreasuryBillSecuritiesMember2025-12-310001682852us-gaap:USTreasuryNotesSecuritiesMember2025-12-310001682852us-gaap:CorporateDebtSecuritiesMember2025-12-310001682852us-gaap:USGovernmentDebtSecuritiesMember2025-12-310001682852us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2026-03-310001682852us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2026-03-310001682852us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2026-03-310001682852us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2026-03-310001682852us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2026-03-310001682852us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2026-03-310001682852us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2026-03-310001682852us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2026-03-310001682852us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2026-03-310001682852us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2026-03-310001682852us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2026-03-310001682852us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2026-03-310001682852us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2026-03-310001682852us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2026-03-310001682852us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2026-03-310001682852us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2026-03-310001682852us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2026-03-310001682852us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2026-03-310001682852us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2026-03-310001682852us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2026-03-310001682852us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2026-03-310001682852us-gaap:FairValueMeasurementsRecurringMember2026-03-310001682852us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2026-03-310001682852us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2026-03-310001682852us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2025-12-310001682852us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2025-12-310001682852us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2025-12-310001682852us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2025-12-310001682852us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2025-12-310001682852us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2025-12-310001682852us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2025-12-310001682852us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2025-12-310001682852us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2025-12-310001682852us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2025-12-310001682852us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2025-12-310001682852us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2025-12-310001682852us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2025-12-310001682852us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2025-12-310001682852us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2025-12-310001682852us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2025-12-310001682852us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2025-12-310001682852us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2025-12-310001682852us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2025-12-310001682852us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2025-12-310001682852us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2025-12-310001682852us-gaap:FairValueMeasurementsRecurringMember2025-12-310001682852us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2025-12-310001682852us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2025-12-310001682852srt:MinimumMembermrna:COVIDVaccineMember2026-01-012026-03-310001682852srt:MaximumMembermrna:COVIDVaccineMember2026-01-012026-03-310001682852mrna:MNEXSPIKEVaccineMember2026-01-012026-03-310001682852mrna:RSVVaccineMember2026-01-012026-03-310001682852us-gaap:LandMember2026-03-310001682852us-gaap:LandMember2025-12-310001682852us-gaap:BuildingAndBuildingImprovementsMember2026-03-310001682852us-gaap:BuildingAndBuildingImprovementsMember2025-12-310001682852us-gaap:EquipmentMember2026-03-310001682852us-gaap:EquipmentMember2025-12-310001682852us-gaap:LeaseholdImprovementsMember2026-03-310001682852us-gaap:LeaseholdImprovementsMember2025-12-310001682852us-gaap:PropertyPlantAndEquipmentOtherTypesMember2026-03-310001682852us-gaap:PropertyPlantAndEquipmentOtherTypesMember2025-12-310001682852us-gaap:ComputerEquipmentMember2026-03-310001682852us-gaap:ComputerEquipmentMember2025-12-310001682852us-gaap:ConstructionInProgressMember2026-03-310001682852us-gaap:ConstructionInProgressMember2025-12-310001682852mrna:FinancingRightOfUseAssetMember2026-03-310001682852mrna:FinancingRightOfUseAssetMember2025-12-310001682852mrna:ArbutusBiopharmaCorporationArbutusAndGenevantSciencesGmbHGenevantMemberus-gaap:IntellectualPropertyMember2026-03-310001682852us-gaap:ProductAndServiceOtherMember2025-12-310001682852us-gaap:ProductAndServiceOtherMember2026-03-310001682852mrna:CambridgeMassachusettsMember2026-03-310001682852mrna:CambridgeMassachusettsMember2023-09-300001682852us-gaap:SecuredDebtMemberus-gaap:LineOfCreditMember2025-11-300001682852us-gaap:SecuredDebtMembermrna:InitialTermLoanMemberus-gaap:LineOfCreditMember2025-11-300001682852us-gaap:SecuredDebtMembermrna:DelayedDrawTermLoanFacilityMemberus-gaap:LineOfCreditMember2025-11-300001682852us-gaap:SecuredDebtMembermrna:DelayedDrawTermLoanFacility1Memberus-gaap:LineOfCreditMember2025-11-300001682852us-gaap:SecuredDebtMembermrna:DelayedDrawTermLoanFacility2Memberus-gaap:LineOfCreditMember2025-11-300001682852us-gaap:SecuredDebtMemberus-gaap:SecuredOvernightFinancingRateSofrMemberus-gaap:LineOfCreditMember2025-11-012025-11-300001682852us-gaap:SecuredDebtMemberus-gaap:BaseRateMemberus-gaap:LineOfCreditMember2025-11-012025-11-300001682852us-gaap:SecuredDebtMemberus-gaap:FederalFundsEffectiveSwapRateMemberus-gaap:LineOfCreditMember2025-11-012025-11-300001682852us-gaap:SecuredDebtMembermrna:TermSecuredOvernightFinancingRatePlusMemberus-gaap:LineOfCreditMember2025-11-012025-11-300001682852us-gaap:SecuredDebtMembermrna:InitialTermLoanMemberus-gaap:LineOfCreditMember2026-03-310001682852us-gaap:SecuredDebtMembermrna:InitialTermLoanMemberus-gaap:LineOfCreditMember2025-12-310001682852us-gaap:SecuredDebtMembermrna:CovenantComplianceScenario1Memberus-gaap:LineOfCreditMember2025-11-300001682852us-gaap:SecuredDebtMembermrna:CovenantComplianceScenario2Memberus-gaap:LineOfCreditMember2025-11-300001682852us-gaap:SecuredDebtMemberus-gaap:LineOfCreditMember2025-11-012025-11-300001682852mrna:ArbutusBiopharmaCorporationArbutusAndGenevantSciencesGmbHGenevantMember2026-03-310001682852mrna:ArbutusBiopharmaCorporationArbutusAndGenevantSciencesGmbHGenevantMember2026-01-012026-03-310001682852mrna:ArbutusBiopharmaCorporationArbutusAndGenevantSciencesGmbHGenevantMembersrt:MaximumMember2026-03-310001682852mrna:GlaxoSmithKlineBiologicalsMember2026-01-012026-03-310001682852us-gaap:IndemnificationGuaranteeMember2026-01-012026-03-310001682852us-gaap:IndemnificationGuaranteeMember2025-01-012025-12-310001682852us-gaap:IndemnificationGuaranteeMember2025-12-310001682852us-gaap:IndemnificationGuaranteeMember2026-03-310001682852mrna:NationalInstituteOfAllergyAndInfectiousDiseasesMemberMember2025-01-012025-01-310001682852mrna:ArbutusBiopharmaCorporationArbutusAndGenevantSciencesGmbHGenevantMember2026-01-012026-03-310001682852us-gaap:EmployeeStockOptionMember2026-01-012026-03-310001682852us-gaap:EmployeeStockOptionMember2025-01-012025-03-310001682852us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-03-310001682852us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-03-310001682852mrna:PerformanceStockUnitMember2026-01-012026-03-310001682852mrna:PerformanceStockUnitMember2025-01-012025-03-310001682852us-gaap:EmployeeStockMember2026-01-012026-03-310001682852us-gaap:EmployeeStockMember2025-01-012025-03-310001682852us-gaap:CostOfSalesMember2026-01-012026-03-310001682852us-gaap:CostOfSalesMember2025-01-012025-03-310001682852us-gaap:ResearchAndDevelopmentExpenseMember2026-01-012026-03-310001682852us-gaap:ResearchAndDevelopmentExpenseMember2025-01-012025-03-310001682852us-gaap:GeneralAndAdministrativeExpenseMember2026-01-012026-03-310001682852us-gaap:GeneralAndAdministrativeExpenseMember2025-01-012025-03-310001682852mrna:A2022RepurchaseProgramMember2026-03-31

☒    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

☐    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒    No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

As of April 24, 2026, there were 396,786,259 shares of the registrant’s common stock, par value $0.0001 per share, outstanding.

This Quarterly Report on Form 10-Q (Form 10-Q) contains express or implied forward-looking statements. All statements other than those of historical facts contained in this Form 10-Q are based on our management’s beliefs and assumptions and on information currently available to our management. Forward-looking statements in this Form 10-Q include, but are not limited to, statements about:

•our ability to drive use of our commercial products and expectations regarding a return to sales growth in 2026;

•our ability to execute on our prioritized research and development portfolio;

•our ability to deliver cost efficiency across our business;

•our expectations regarding the size and durability of the respiratory vaccine market;

•the availability of mCOMBRIAX across the EU, subject to national regulatory and access procedures;

•our long-term strategic partnerships with government entities;

•anticipated near-term regulatory actions for our product candidates, including potential filings, reviews and approvals;

•anticipated milestones for our pipeline programs, including potential data readouts and other near-term catalysts;

•our ability to obtain and maintain regulatory approval of our product candidates across our portfolio;

•our ability to successfully launch and commercialize our products and the timing of launches;

•the potential of our oncology portfolio;

•our ability and the ability of third parties with whom we contract to successfully manufacture, supply and distribute our commercial products and any future commercial products at scale, as well as drug substances, delivery vehicles, development candidates, and investigational medicines for preclinical and clinical use;

•financing and funding options we may consider as part of our research and development strategy;

•our ability to successfully contract with third-party suppliers, distributors and manufacturers;

•internal and external costs associated with manufacturing our products and the impact on our cost of sales, and our anticipated cost of sales as a percentage of net product sales;

•the scope of protection we are able to establish and maintain for intellectual property rights, including those covering our commercial products, product candidates and technology, and our expectations regarding pending legal proceedings related to our intellectual property;

•the timing of initiation, progress, completion, results and cost of our clinical trials, preclinical studies and research and development programs, as well as those of our collaborators;

•participant enrollment in our clinical trials, including timing;

•potential advantages of mRNA as compared to traditional medicine;

•the implementation of our business model and strategic plans for our business, products, product candidates and technology;

•the pricing and reimbursement of our products, if approved;

•the build out of our manufacturing and commercial operations;

•estimates of our future expenses, revenues and capital requirements;

•our operation and funding requirements, including our forecast of the period of time through which our financial resources will be adequate to support our operations;

•the potential benefits of strategic collaboration agreements and our ability to enter into strategic collaborations or other agreements with collaborators with development, regulatory and commercialization expertise;

•our financial performance;

•our tax positions and related tax liabilities;

•legal and regulatory developments in the United States and foreign countries;

•our ability to produce our products or product candidates with advantages in turnaround times or manufacturing cost; and

•developments relating to our competitors and our industry.

Forward-looking statements often contain words such as “will,” “may,” “should,” “could,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our operational or financial performance, and involve risks, uncertainties, and other factors that may cause our actual results to differ materially from any future results expressed or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the section entitled “Risk Factors” and elsewhere in this Form 10-Q and under Part I, Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual results could differ materially from those expressed or implied by the forward-looking statements.

The forward-looking statements in this Form 10-Q represent our views as of the date of this Form 10-Q. We undertake no obligation to update any forward-looking statements, except as required by applicable securities law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Form 10-Q. However, any further disclosures made on related subjects in our subsequent reports filed with the Securities and Exchange Commission should be consulted.

This Form 10-Q contains references to our trademarks and to trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to may appear without the ® or ™ symbols, but such references are not intended to indicate that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend our reference to other companies’ trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

Unless the context otherwise requires, the terms “Moderna,” the “Company,” “we,” “us” and “our” in this Form 10-Q refer to Moderna, Inc. and its consolidated subsidiaries.

Our website, www.modernatx.com, including the Investor Relations section, www.investors.modernatx.com; and corporate blog www.modernatx.com/moderna-blog, and our Statements and Perspectives webpage, https://investors.modernatx.com/Statements--Perspectives/default.aspx; as well as our social media channels: Facebook, www.facebook.com/modernatx; X, www.x.com/moderna_tx (@moderna_tx); LinkedIn, www.linkedin.com/company/modernatx; Instagram (@moderna_tx); and Threads (@moderna_tx) contain a significant amount of information about us, including financial and other information for investors. We encourage investors to visit these websites and social media channels as information is frequently updated and new information is shared. Information contained on our website, corporate blog and social media channels shall not be deemed incorporated into, or be a part of, this Form 10-Q.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

Moderna, Inc. (collectively, with its consolidated subsidiaries, any of Moderna, we, us, our or the Company) is a biotechnology company advancing a new class of medicines made of messenger RNA (mRNA). mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a broad spectrum of diseases. Our platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing us the capability to pursue in parallel a robust pipeline of new development candidates. We are developing medicines across infectious disease vaccines, oncology therapeutics and rare disease therapeutics.

Since our founding in 2010, we have transformed from a research-stage company advancing programs in the field of mRNA to a commercial enterprise with a diverse clinical portfolio of vaccines and therapeutics across several modalities, a broad intellectual property portfolio and integrated manufacturing capabilities that allow for rapid clinical and commercial production at scale. As of March 31, 2026, we had three commercial products—Spikevax® and mNEXSPIKE®, our COVID vaccines, and mRESVIA®, our vaccine against respiratory syncytial virus (RSV). Additionally, we have a diverse development pipeline of 25 development candidates across our 35 development programs currently in clinical studies.

The accompanying unaudited condensed consolidated financial statements that accompany these notes have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) for interim financial reporting, consistent in all material respects with those applied in our Annual Report on Form 10-K for the year ended December 31, 2025 (2025 Form 10-K). Any reference in these notes to applicable guidance is meant to refer to the authoritative accounting principles generally accepted in the United States as found in the Accounting Standards Codification (ASC) and Accounting Standards Update (ASU) of the Financial Accounting Standards Board (FASB). This report should be read in conjunction with the audited consolidated financial statements in our 2025 Form 10-K.

The condensed consolidated financial statements include Moderna, Inc. and its subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. The significant accounting policies used in the preparation of these condensed consolidated financial statements for the three months ended March 31, 2026 are consistent with those described in our 2025 Form 10-K. The results of operations for the three months ended March 31, 2026 are not necessarily indicative of the operating results to be expected for the full fiscal year or future operating periods. We anticipate seasonal fluctuations in demand for our COVID and RSV vaccines, with higher sales expected during the fall and winter seasons.

We have made estimates and judgments affecting the amounts reported in our condensed consolidated financial statements and the accompanying notes. We base our estimates on historical experience and various relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods that are not readily apparent from other sources. Changes in our estimates are recorded in the financial results of the period in which the new information becomes available. The actual results that we experience may differ materially from our estimates.

Comprehensive income (loss) includes net income (loss) and other comprehensive income/loss for the period. Other comprehensive income/loss consists of unrealized gains/losses on our investments, derivatives designated as hedging instruments, foreign currency translation, and pension and postretirement obligation adjustments. Total comprehensive income (loss) for all periods presented has been disclosed in the condensed consolidated statements of comprehensive income (loss).

The components of accumulated other comprehensive income (loss) for the three months ended March 31, 2026 were as follows (in millions): 

We include our restricted cash balance in the cash, cash equivalents and restricted cash reconciliation of operating, investing and financing activities in the condensed consolidated statements of cash flows. 

The following table provides a reconciliation of cash, cash equivalents and restricted cash in the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows (in millions):

_______

(1)Included in prepaid expenses and other current assets in the condensed consolidated balance sheets.

(2)Included in other non-current assets in the condensed consolidated balance sheets.

From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by us as of the specified effective date. Except as noted below, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our condensed consolidated financial statements and disclosures.

In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. This ASU requires entities to disclose, on an annual and interim basis, disaggregated information in the footnotes related to certain expense categories included in income statement line items. Specifically, entities are expected to provide tabular disclosures for prescribed categories such as inventory purchases, employee compensation, depreciation, and intangible asset amortization for each relevant expense caption. The standard also requires disclosure of total selling expenses and a definition of those expenses in annual filings. Any remaining amounts not quantitatively disclosed are expected to be described qualitatively. This ASU is effective for fiscal years beginning after December 15, 2026 and interim periods beginning after December 15, 2027. Early adoption permitted, and the standard may be applied on a prospective or retrospective basis. We are currently assessing the impact that this new accounting standard will have on our consolidated financial statement disclosures.

In September 2025, the FASB issued ASU No. 2025-06, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software. This ASU makes targeted amendments to the accounting for and disclosure of software costs under ASC 350-40. The amendments modernize the guidance to reflect current software development practices, including nonlinear development approaches, and remove references to “development stages.” Under the ASU, the following two criteria must be met for entities to begin capitalizing software costs: (1) management, with the relevant authority, implicitly or explicitly authorizes and commits to funding a computer software project, and (2) it is probable that the project will be completed and the software will be used to perform the function intended (referred to as the “probable-to-complete recognition threshold”). The ASU clarifies that this threshold would not be met when there is “significant uncertainty associated with the development activities of the software (referred to as ‘significant development uncertainty’).” The new standard is effective for all entities for annual reporting periods beginning after December 15, 2027, and for interim reporting periods within those fiscal years. Early adoption is permitted, and entities may apply the amendments prospectively, retrospectively, or using a modified prospective transition approach. We are currently evaluating the impact that this new accounting standard will have on our consolidated financial statements and disclosures.

In September 2025, the FASB issued ASU No. 2025-07, Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic 606): Derivatives Scope Refinements and Scope Clarification for Share-Based Noncash Consideration From a Customer in a Revenue Contract. This ASU expands the scope exceptions in the derivatives guidance to exclude certain non-exchange-traded contracts with underlyings based on the operations or activities of one of the parties to the contract, including the occurrence or nonoccurrence of an event specific to those operations or activities. The ASU also clarifies that share-based noncash consideration received from a customer in exchange for goods or services should be accounted for as noncash consideration under ASC 606 unless and until the entity’s right to receive or retain such consideration becomes unconditional. The ASU is effective for annual reporting periods beginning after December 15, 2026, including interim periods within those annual reporting periods. Early adoption is permitted. We are currently evaluating the impact that adoption of this new accounting standard will have on our consolidated financial statements and disclosures.

In December 2025, the FASB issued ASU No. 2025-10, Government Grants (Topic 832): Accounting for Government Grants Received by Business Entities. This ASU establishes guidance on the recognition, measurement, presentation, and disclosure of government grants received by business entities. The guidance defines a government grant as a transfer of a monetary asset or a tangible nonmonetary asset from a government to a business entity other than in an exchange transaction and excludes transactions within the scope of other U.S. GAAP. Under the ASU, government grants are classified as either grants related to an asset or grants related to income, and recognition is permitted only when it is probable that the entity will comply with the conditions attached to the grant and that the grant will be received. The ASU permits alternative presentation approaches depending on the nature of the grant and requires disclosures regarding the nature of the grant, affected financial statement line items, and significant terms and conditions. The ASU is effective for public business entities for annual reporting periods beginning after December 15, 2028, including interim periods within those annual reporting periods. Early adoption is permitted, and the standard may be applied on a modified prospective, modified retrospective, or full retrospective basis. We are currently evaluating the impact of this new accounting standard and do not expect its adoption to have a material impact on our consolidated financial statements and disclosures.

Net product sales by product type were as follows (in millions):

_______

(1)Includes sales of Spikevax and mNEXSPIKE.

As of March 31, 2026, we have three commercial products, our COVID vaccines, Spikevax and mNEXSPIKE, and our RSV vaccine, mRESVIA. mRESVIA was approved by the FDA in May 2024 for adults aged 60 years and older, and in June 2025, the approved use was expanded to include adults aged 18 through 59 years who are at increased risk for lower respiratory tract disease caused by RSV. In May 2025, mNEXSPIKE was approved for use in adults aged 65 years and older, as well as individuals aged 12 through 64 years with at least one underlying risk factor. We launched commercial sales of mNEXSPIKE in the third quarter of 2025.

We sell our COVID and RSV vaccines to the commercial market as well as to foreign governments and international organizations. In the U.S., our COVID and RSV vaccines are sold primarily to wholesalers and distributors, and to a lesser extent, directly to retailers and healthcare providers. Wholesalers and distributors typically do not make upfront payments to us. Net product sales are recognized net of estimated wholesaler chargebacks, invoice discounts for prompt payments and pre-orders, provisions for sales returns and government rebates, and other related deductions.

The following table summarizes product sales provision adjustments for the periods presented (in millions):

						Three Months Ended March 31,
						2026						2025
Gross product sales						$	350					$	105
Product sales provision:
Wholesaler chargebacks, discounts and fees						11						(22)
Returns, rebates and other fees						(9)						3
Total product sales provision adjustments						$	2					$	(19)
Net product sales						$	352					$	86

The following table summarizes the activities related to product sales provision recorded as accrued liabilities for the three months ended March 31, 2026 (in millions):

The following table summarizes other revenue for the periods presented (in millions):

Merck – Individualized Neoantigen Therapy (Intismeran Autogene)

In June 2016, we entered into a Collaboration and License Agreement, which was subsequently amended in 2018, with Merck & Co., Inc. (Merck) for the development and commercialization of individualized neoantigen therapy (INT), which has been assigned the generic name intismeran autogene.

In September 2022, Merck exercised its option for intismeran, including mRNA-4157, pursuant to the terms of the agreement and in October 2022 paid us an option exercise fee of $250 million. Following this exercise, the Merck Participation Term commenced. Pursuant to the agreement, we and Merck have agreed to collaborate on development and potential commercialization of intismeran, with costs and any profits or losses generally shared equally on a worldwide basis, subject to certain exceptions as outlined in the agreement. During the development phase, we are primarily responsible for process development and the manufacture of intismeran materials, while Merck generally leads clinical trials. We concluded that the collaboration arrangement under the Merck Participation Term is within the scope of ASC 808. For the three months ended March 31, 2026 and 2025, we recognized expenses, net of Merck's reimbursements, of $101 million and $104 million, respectively, related to the INT collaboration under the Merck Participation Term. Additionally, for the three months ended March 31, 2026 and 2025, the net cost recovery for capital expenditures was $1 million and $12 million, respectively. These amounts were applied to reduce the capitalized cost of the assets.

In January 2026, we entered into a collaboration agreement with Recordati S.p.A. (Recordati) to advance the development and commercialization of our investigational propionic acidemia therapeutic, mRNA-3927. Under the terms of the agreement, we granted Recordati an exclusive, royalty-bearing license to develop and commercialize the licensed product (mRNA-3927) worldwide, we will perform and continue to lead clinical development activities through approval, and Recordati will lead global commercialization upon approval. The transaction closed on March 16, 2026, and we are entitled to receive a $50 million upfront payment. As of March 31, 2026, we recorded a receivable and deferred revenue for this amount, which is expected to be recognized as collaboration revenue over time. In addition, we are eligible to receive up to $110 million in development and regulatory milestones, as well as additional commercial and sales milestones and tiered royalties on net sales.

We have other collaborative and licensing arrangements that we do not consider to be individually significant to our business at this time. Pursuant to these agreements, we may be required to make upfront payments and payments upon achievement of various development, regulatory and commercial milestones, which in the aggregate could be significant. Future milestone payments, if any, will be reflected in our consolidated financial statements when the corresponding events have occurred. In addition, we may be required to pay significant royalties on future sales if products related to these arrangements are commercialized.

In March 2024, we entered into a development and commercialization funding arrangement with Blackstone, under which Blackstone has committed to providing up to $750 million in funding to us. This funding supports the development of our investigational mRNA-based influenza vaccine. Contingent upon regulatory approval in the U.S. and only if the approval is dependent on data from the funded activities, Blackstone will be entitled to receive low single-digit percentage royalties and up to $750 million in sales milestone payments. These payments are based on net sales of our future influenza and combination vaccines, with sales milestone payments contingent upon achieving specified cumulative net sales targets.

Given the substantive transfer of financial risk to Blackstone, we account for this arrangement as an obligation to conduct research and development activities. The funding is recognized as a reduction to the expenses of our mRNA-based influenza program. This reduction is recognized proportionally as the related costs are incurred, based on an input method. For the three months ended March 31, 2026 and 2025, we recorded expense reductions of $50 million and $90 million, respectively.

The following tables summarize our cash, cash equivalents, and available-for-sale securities by significant investment category as of March 31, 2026 and December 31, 2025 (in millions):

The amortized cost and estimated fair value of available-for-sale securities by contractual maturity as of March 31, 2026 and December 31, 2025 were as follows (in millions):

In accordance with our investment policy, we place investments in investment grade securities with high credit quality issuers, and generally limit the amount of credit exposure to any one issuer. We evaluate securities for impairment at the end of each reporting period. Impairment is evaluated considering numerous factors, and their relative significance varies depending on the situation.

Factors considered include whether a decline in fair value below the amortized cost basis is due to credit-related factors or non-credit-related factors, the financial condition and near-term prospects of the issuer, and our intent and ability to hold the investment to allow for an anticipated recovery in fair value. Any impairment that is not credit related is recognized in other comprehensive loss, net of applicable taxes. A credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings. We did not recognize any impairment charges related to available-for-sale securities for the three months ended March 31, 2026 and 2025. We did not record any credit-related allowance for available-for-sale securities as of March 31, 2026 and December 31, 2025.

The following table summarizes the amount of gross unrealized losses and the estimated fair value for our available-for-sale securities in an unrealized loss position by the length of time the securities have been in an unrealized loss position as of March 31, 2026 and December 31, 2025 (in millions):

As of March 31, 2026 and December 31, 2025, we held 292 and 108 available-for-sale securities, respectively, out of our total investment portfolio that were in a continuous unrealized loss position. We neither intend to sell these investments, nor do we believe that we are more-likely-than-not to conclude we will have to sell them before recovery of their carrying values. We also believe that we will be able to collect both principal and interest amounts due to us at maturity.

The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used to value the assets and liabilities:

•Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

•Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; or

•Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

The following tables summarize our financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2026 and December 31, 2025 (in millions):

_______

(1)Investments in publicly traded equity securities with readily determinable fair values are recorded at quoted market prices for identical securities, with changes in fair value recorded in other expense, net, in our condensed consolidated statements of operations.

As of March 31, 2026 and December 31, 2025, we did not have non-financial assets or liabilities measured at fair value on a recurring basis and did not have any Level 3 financial assets or financial liabilities.

For the three months ended March 31, 2026 and 2025, we recognized net losses of $2 million and $8 million, respectively, on equity investments from changes in fair value of the securities.

We estimate the fair value of our term loan using Level 2 inputs. The fair value of the term loan approximates its carrying value as of March 31, 2026 and December 31, 2025, as the instrument bears interest at a variable rate that reflects current market rates. See Note 11 for additional information.

Inventory as of March 31, 2026 and December 31, 2025 consisted of the following (in millions):

_______

(1)Consisted of raw materials with an anticipated consumption beyond one year. Inventory, non-current is included in other non-current assets in the condensed consolidated balance sheets.

Inventory write-downs as a result of excess, obsolescence, scrap or other reasons, and losses on firm purchase commitments are recorded as a component of cost of sales in our condensed consolidated statements of operations. For the three months ended March 31, 2026 and 2025, inventory write-downs were $38 million and $42 million, respectively. For the three months ended March 31, 2026, there were no losses on firm purchase commitments. For the three months ended March 31, 2025, losses on firm purchase commitments was $10 million.

Inventory write-downs were mainly related to inventory in excess of expected demand, shelf-life expiration and other inventory adjustments. Losses on firm purchase commitments were primarily related to excess raw material purchase commitments that will expire before the anticipated consumption of those raw materials.

As of March 31, 2026 and December 31, 2025, we had inventory on hand of $263 million and $267 million, respectively, inclusive of inventory for our COVID and RSV vaccines. Our raw materials and work-in-progress inventory have variable shelf lives. We expect that the majority of this inventory will be consumed over the next three years. The shelf life of Spikevax is nine to twelve months. mNEXSPIKE has a shelf life of twelve months. The shelf life of mRESVIA, our RSV vaccine, is eighteen months.

Property, plant and equipment, net, as of March 31, 2026 and December 31, 2025 consisted of the following (in millions):

Depreciation and amortization expense related to property, plant and equipment for the three months ended March 31, 2026 and 2025 was $56 million and $38 million, respectively.

Accounts receivable, net, as of March 31, 2026 and December 31, 2025 consisted of the following (in millions):

Prepaid expenses and other current assets, as of March 31, 2026 and December 31, 2025 consisted of the following (in millions):

Other non-current assets, as of March 31, 2026 and December 31, 2025 consisted of the following (in millions):

						March 31,						December 31,
						2026						2025
Income tax receivable, non-current						$	161					$	161
Inventory, non-current(1)						117						114
Finite-lived intangible assets, net(2)						116						45
Down payments and prepayments, non-current						97						100
Deferred tax assets						82						81
Goodwill						52						52
Other						50						52
Other non-current assets						$	675					$	605

_______

(1)Consisted of raw materials with an anticipated consumption beyond one year.

(2)Includes a $72 million intangible asset related to a license recognized in connection with the settlement agreement with Arbutus and Genevant. See Note 12 for additional details.

Accrued liabilities, as of March 31, 2026 and December 31, 2025 consisted of the following (in millions):

______

(1) Includes $950 million related to the litigation settlement with Arbutus and Genevant (Note 12).

(2) Related to losses that are expected to arise from firm, non-cancellable, commitments for future raw material purchases (Note 7).

Other current liabilities, as of March 31, 2026 and December 31, 2025 consisted of the following (in millions):

Other non-current liabilities, as of March 31, 2026 and December 31, 2025 consisted of the following (in millions):

The following table summarizes the activities in deferred revenue for the three months ended March 31, 2026 (in millions):

We have entered into various long-term, non-cancelable lease arrangements for our facilities and equipment, expiring at various times through 2039. Certain of these arrangements have free rent periods or escalating rent payment provisions. We recognize lease costs under such arrangements on a straight-line basis over the life of the lease. We lease various parcels of land, office, lab, and manufacturing spaces across the globe for our business operations.

Our primary leased campus is our Moderna Science Center (MSC), located in Cambridge, which serves as our headquarters. The MSC, comprising approximately 462,000 square feet, includes our principal executive office and additional office and laboratory spaces. The MSC lease commenced in the third quarter of 2023 and has a term of 15 years, with options for two additional seven-year extensions.

Operating and financing lease right-of-use assets and lease liabilities as of March 31, 2026 and December 31, 2025 were as follows (in millions):

_______

(1)These assets are real estate related assets, which include land, office, manufacturing, and laboratory spaces.

(2)Net of accumulated amortization.

(3)These assets are related to contract manufacturing service agreements.

(4)Included in property, plant and equipment in the condensed consolidated balance sheets, net of accumulated depreciation.

(5)Included in other current liabilities in the condensed consolidated balance sheets.

Future minimum lease payments under our non-cancelable lease agreements as of March 31, 2026, were as follows (in millions):